European Nuclear Society’s Post

Plus Therapeutics presented data on its novel radioisotope rhenium-186 at the annual meeting of the Society of Nuclear Medicine & Molecular Imaging (SNMMI) in Toronto. Link to presentation: https://bit.ly/4bd9GyB An oral presentation titled, “Radiation Absorbed Dose to Spinal Cord: Therapy of Leptomeningeal Metastases Using Beta-Emission Pharmaceuticals”, brief highlights: - Data from the ReSPECT-LM clinical trial was used to evaluate the safety and potential spinal cord toxicity of beta-emission radioisotopes, including 177Lu, 131I, 186Re, 188Re, and 90Y - Higher beta-energy emitters (i.e., 188Re and 90Y) give higher radiation absorbed doses to spinal cord with more heterogeneous radiation absorbed doses to spinal fluid - Lower beta-energy radionuclides (177Lu, 131I, and 186Re) can largely spare the spinal cord, presenting a promising approach to minimize toxicity while delivering high doses to eradicate cancer cells #nuclearmedicine #clinicaltrials #radiotherapy

Fun Fact Friday! 🧠💡 Did you know? FDG (Fluorodeoxyglucose), a radiopharmaceutical widely used in PET scans, has a very short half-life of just 110-115 minutes! ⏳ What does this mean? The half-life is the time it takes for half of the radioactive material to decay. So, within 110-115 minutes, half of the FDG no longer emits the radiation needed for medical imaging. That's why FDG must be produced near the site where it will be used and administered shortly after production to ensure its effectiveness in detecting diseases like cancer. 🏥⚛️ FDG is typically produced in facilities equipped with a cyclotron, a machine that accelerates particles to create radioactive isotopes. From there, the FDG is quickly transported to hospitals or diagnostic centers, ensuring that imaging can be done before the FDG loses its potency. This rapid coordination is crucial for providing accurate diagnostic results. FDG highlights how time is of the essence in nuclear medicine. So, the next time you hear about a PET scan, remember the critical role FDG plays and how quickly it needs to be used! 🔬💡 #IMSFunFactFriday #FDG #PETScan #NuclearMedicine #MedicalImaging #Radiopharmaceuticals #Cyclotron

In the realm of nuclear medicine, a transformative shift is underway, thanks to the bold strides being made by big pharma in embracing and investing in radiopharmaceuticals, particularly RadioLigand Therapy (RLT). This pioneering approach is not just about advancing medical technology; it’s about bringing hope and cutting-edge treatment options closer to practitioners and patients alike. Radiopharmaceuticals represent a unique fusion of chemistry, physics, and medicine, offering targeted therapies that deliver radiation directly to the tumor site, minimizing damage to surrounding healthy tissues. The spotlight on RLT is especially promising, offering a new horizon for patients with various types of cancer. The commitment of major pharmaceutical companies to this sector is a testament to the potential they see in radiopharmaceuticals. Their investments are fueling research, development, and the scaling of production facilities, making these advanced treatments more accessible. For us in the nuclear medicine community, this support is invaluable. It not only accelerates the path to innovative treatments but also fosters a collaborative ecosystem where knowledge, expertise, and resources are shared towards a common goal - improving patient outcomes. As we stand on the cusp of this new era in medicine, let’s celebrate the convergence of technology, science, and healthcare that radiopharmaceuticals embody. Here’s to a future where advanced therapies like RLT become a cornerstone in the fight against cancer, offering patients new hope and a chance at a healthier life. Credit: My 7 years old drawing… Bravo Yara #Radiopharmaceuticals #NuclearMedicine #RLT

PanTera was set up in September 2022 as a joint venture between Belgium’s nuclear research centre SCK CEN and IBN (Ion Beam Applications) with the mission to commercialise the production of Ac-225 from radium-226 (Ra-226) with the use of accelerator technology. Ac-225 is a promising alpha emitter for use in targeted alpha therapy. It has the potential to target solid tumors, metastases, and systemic cancers such as leukemia. The company’s production method transforms Ra-226 into Ra-225, which then decays into Ac-225. This process will enable PanTera to produce over 100 Curies of clinical-grade Ac-225. annually by 2029, enough to treat more than 100,000 cancer patients each year.  #Nuclear #AdvancedNuclear #SGEC  https://lnkd.in/eyYG43aT

Last week, ARTBIO Chief Scientific Officer Nick Pullen attended the 3rd Annual Targeted Radiopharmaceuticals Summit in San Diego, an invigorating meeting that promoted high-quality dialogue among nuclear medicine specialists and pharma leaders in #radiotherapy.   The Summit highlighted the growing importance of #targeted #radioligand #therapy (TRT), with key experts discussing its advancements and potential. Nick delivered the Opening and Closing remarks and chaired panels on new #radioisotope #targeting technologies, novel payload approaches, and optimizing #nuclearmedicine in the clinic on the first day. Additional key highlights coming from the meeting included discussions around: - The safety and efficacy of various radioisotopes, particularly #Lead212 - The impact of innovative strategies like covalent ligand approaches, pre-targeting, and QSP modeling in advancing combination-based therapies - Emerging clinical results from NETTER-2 and other studies challenging the placement of TRT in the traditional clinical treatment paradigm   ARTBIO is dedicated to redefining cancer care with a new class of #alpha #radioligand #therapies. The insights gained from this summit hold great value for advancing our pipeline and maximizing the potential of our #Pb212 therapies.   Learn more about ARTBIO’s novel approach here: www.artbio.com   #TargetedRadiopharmaceuticals #radioligandtherapy #RLT #biotech #ART

Bromo Biliaron is a radiopharmaceutical used in hepatobiliary imaging, and it contains bromotrimethylaminomethyliminodiacetic acid (mebrofenin) labeled with the radioisotope technetium-99m (Tc-99m). Tc-99m Mebrofenin (technetium-99m mebrofenin) is a radiopharmaceutical used in nuclear medicine, primarily for hepatobiliary imaging. It helps in evaluating liver function, gallbladder function, and the patency of the bile ducts. Technetium-99m (Tc-99m) is a widely used radioisotope in diagnostic imaging because of its ideal physical characteristics, including a half-life of approximately 6 hours and the emission of gamma rays suitable for detection with a gamma camera. 🖇️ Mechanism of Action After intravenous injection, mebrofenin is taken up by hepatocytes and excreted into the bile. The Tc-99m emits gamma rays, which can be detected by a gamma camera to produce images of the hepatobiliary system. Photo by: Dame Ria Silaban #nuclearmedicine

#Protein_arginine_N_methyltransferase5 (PRMT5) has been identified as a potential #therapeutic target for various cancer types. However, its role in regulating the #hepatocellular_carcinoma (HCC) transcriptome remains poorly understood. findings of this study revealed that #PRMT5 is significantly overexpressed in HCC compared to normal #liver, and elevated expression correlates with poor overall survival. Pathway analysis of PRMT5 knockdown in the HCC cells revealed a connection between PRMT5 expression and genes related to the #HIF1α_pathway. Additionally, by filtering PRMT5-correlated genes within the HIF1α pathway and selecting up/downregulated genes in HCC patients, Ras-related nuclear protein (RAN) is a target associated with overall survival. So PRMT5 is implicated in the regulation of HIF1A and RAN genes, suggesting the potential prognostic utility of PRMT5 in HCC REF: https://lnkd.in/d_m933vR #Protein_arginine_N_methyltransferase5 #hepatocellular_carcinoma #PRMT5 #liver #HIF1α_pathway #Molecular_targeted_therapy #Biomarker

The November 2024 issue of the Journal of Nuclear Medicine is out now! Highlights include: >Editor's Page: The Costs to Our Patients >State of the Art: Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy >Is It Really Happening? The Clinical Application of CXCR4 Imaging in the Diagnosis of Management of Primary Aldosteronism >Featured: Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study >Featured: Preclinical Evaluation of Ac-226 as a Theranostic Agent: Imaging, Dosimetry, and Therapy Read the full issue here: https://lnkd.in/egEQpeDJ

FAP-imaging and theranostic in nuclear medicine is further on the way in the clinical space. I kindly would like to share with you our recent invited review article on this topic in https://lnkd.in/eUNvVm-i

#𝗡𝘂𝗰𝗹𝗲𝗮𝗿 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲/𝗥𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝗼𝗻 𝗮 𝗚𝗿𝗼𝘄𝘁𝗵 𝗧𝗿𝗮𝗷𝗲𝗰𝘁𝗼𝗿𝘆! In 2023, the Nuclear Medicine/Radiopharmaceuticals market was valued at US $6.04 Bn, and it's expected to soar to US $11.05 Bn by 2030, growing at a robust CAGR of 9%! 📈 𝗟𝗲𝘁'𝘀 𝗵𝗮𝗿𝗻𝗲𝘀𝘀 𝘁𝗵𝗲 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗼𝗳 𝗻𝘂𝗰𝗹𝗲𝗮𝗿 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝘁𝗼 𝗿𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘇𝗲 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲!https://lnkd.in/gyk72f_N 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗮𝗻𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗣𝗼𝘄𝗲𝗿: Crucial for diagnosing and treating diseases that conventional medicine struggles with. 𝗦𝗣𝗘𝗖𝗧 𝗟𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗪𝗮𝘆: Expected to register the highest growth due to its extensive use in diagnosing cancer, cardiovascular, thyroid, and neurological disorders. 𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗚𝗿𝗼𝘄𝘁𝗵: North America leads the charge, followed by Europe and APAC, thanks to advanced healthcare infrastructure and growing awareness of radiopharmaceutical benefits. Despite high equipment costs, the increasing incidence of cancer and cardiac ailments continues to drive market growth. #NuclearMedicine #Radiopharmaceuticals #HealthcareInnovation #MarketGrowth #MedicalImaging #Therapeutics #HealthcareIndustry #FutureOfMedicine